{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T15:45:09Z","timestamp":1792856709625,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T00:00:00Z","timestamp":1726617600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ekir.2024.09.014","type":"journal-article","created":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T12:42:44Z","timestamp":1727181764000},"page":"3490-3500","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["SGLT2-Inhibition in Patients With Alport Syndrome"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9170-1579","authenticated-orcid":false,"given":"Jan","family":"Boeckhaus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel P.","family":"Gale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Neil","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3900-1735","authenticated-orcid":false,"given":"Matthew","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Sayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalabh","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Gyung","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agne","family":"Cerkauskaite-Kerpauskiene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentine","family":"Gillion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen J.","family":"Claes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastian","family":"Krueger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"de Fallois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Walden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mira","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Schueler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman-Ulrich","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polina","family":"Todorova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Hohenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Zeisberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Friede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Knebelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Halbritter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2024.09.014_bib1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S2213-8587(23)00321-2","article-title":"Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial","volume":"12","author":"Staplin","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ekir.2024.09.014_bib2","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2024.09.014_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ekir.2024.09.014_bib4","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2024.09.014_bib5","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2024.09.014_bib6","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1056\/NEJMra022296","article-title":"Alport\u2019s syndrome, Goodpasture\u2019s syndrome, and Type IV collagen","volume":"348","author":"Hudson","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2024.09.014_bib7","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1806891","article-title":"Diagnostic utility of exome sequencing for kidney disease","volume":"380","author":"Groopman","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2024.09.014_bib8","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.kint.2017.12.018","article-title":"Alport syndrome: a unified classification of genetic disorders of collagen IV \u03b1345: a position paper of the Alport Syndrome Classification Working Group","volume":"93","author":"Kashtan","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2024.09.014_bib9","first-page":"1157","article-title":"A\u00a0mutation causing Alport syndrome with tardive hearing loss is common in the western United States","volume":"58","author":"Barker","year":"1996","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.ekir.2024.09.014_bib10","article-title":"Characterization of sensorineural hearing loss in children with Alport syndrome","volume":"10","author":"Boeckhaus","year":"2020","journal-title":"Life (Basel)"},{"key":"10.1016\/j.ekir.2024.09.014_bib11","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/nrneph.2012.259","article-title":"Alport syndrome-insights from basic and clinical research","volume":"9","author":"Kruegel","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2024.09.014_bib12","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s004670050804","article-title":"Alport syndromes: phenotypic heterogeneity of progressive hereditary nephritis","volume":"14","author":"Kashtan","year":"2000","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2024.09.014_bib13","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/cge.13861","article-title":"Precise variant interpretation, phenotype ascertainment, and genotype-phenotype correlation of children in the EARLY PRO-TECT Alport trial","volume":"99","author":"Boeckhaus","year":"2021","journal-title":"Clin Genet"},{"key":"10.1016\/j.ekir.2024.09.014_bib14","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/ejhg.2014.254","article-title":"Clinical utility gene card for: Alport syndrome - update 2014","volume":"23","author":"Hertz","year":"2015","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.ekir.2024.09.014_bib15","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1681\/ASN.V114649","article-title":"X-linked Alport syndrome: natural history in 195 families and genotype- phenotype correlations in males","volume":"11","author":"Jais","year":"2000","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2024.09.014_bib16","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1042\/CS20191276","article-title":"SGLT2 inhibitors - a potential treatment for Alport syndrome","volume":"134","author":"Mabillard","year":"2020","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.ekir.2024.09.014_bib17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-8587(23)00322-4","article-title":"Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial","volume":"12","author":"Judge","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ekir.2024.09.014_bib18","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1016\/j.ekir.2022.06.017","article-title":"Efficacy of Dapagliflozin in Adult Autosomal Recessive Alport Syndrome","volume":"7","author":"Li","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2024.09.014_bib19","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.3390\/cells10071815","article-title":"Sodium-glucose Cotransporter-2 inhibitors in patients with hereditary podocytopathies, Alport syndrome, and FSGS: a case series to better plan a large-scale study","volume":"10","author":"Boeckhaus","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.ekir.2024.09.014_bib20","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ekir.2021.12.019","article-title":"Efficacy and Safety of Dapagliflozin in Children With Inherited Proteinuric Kidney Disease: A Pilot\u00a0Study","volume":"7","author":"Liu","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2024.09.014_bib21","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S2213-8587(18)30314-0","article-title":"Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials","volume":"7","author":"Heerspink","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ekir.2024.09.014_bib22","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41431-022-01075-0","article-title":"The 2019 and 2021 international workshops on Alport syndrome","volume":"30","author":"Daga","year":"2022","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.ekir.2024.09.014_bib23","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.3390\/cells12091333","article-title":"Ratio of urinary proteins to albumin excretion shifts substantially during progression of the podocytopathy Alport syndrome, and spot urine is a reliable method to detect these pathologic changes","volume":"12","author":"Boeckhaus","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.ekir.2024.09.014_bib24","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/j.ekir.2024.02.1404","article-title":"Fournier\u2019s gangrene in a patient with CKD without diabetes possibly related to sodium glucose co-transporter 2 inhibitor therapy","volume":"9","author":"Heidegger","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2024.09.014_bib25","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","article-title":"Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition","volume":"60","author":"Vallon","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.ekir.2024.09.014_bib26","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1007\/s00125-014-3396-4","article-title":"Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration","volume":"57","author":"\u0160krti\u0107","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.ekir.2024.09.014_bib27","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S2213-8587(17)30182-1","article-title":"Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial","volume":"5","author":"Cherney","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ekir.2024.09.014_bib28","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S2213-8587(19)30118-4","article-title":"Predicting individual treatment response in diabetes","volume":"7","author":"Heerspink","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ekir.2024.09.014_bib29","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/j.kint.2020.06.038","article-title":"Genotype-phenotype correlations influence the response to angiotensin-targeting drugs in Japanese patients with male X-linked Alport syndrome","volume":"98","author":"Yamamura","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2024.09.014_bib30","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.ekir.2022.04.094","article-title":"Prescribing SGLT2 inhibitors in patients with CKD: expanding indications and practical considerations","volume":"7","author":"Yau","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2024.09.014_bib31","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","article-title":"A\u00a0pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy","volume":"100","author":"Wheeler","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2024.09.014_bib32","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1093\/ndt\/gfab335","article-title":"Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial","volume":"37","author":"Wheeler","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2024.09.014_bib33","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(23)02843-X","article-title":"Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort","volume":"0","author":"Wong","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2024.09.014_bib34","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1007\/s00125-018-4669-0","article-title":"The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure","volume":"61","author":"Thomas","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.ekir.2024.09.014_bib35","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Lambers Heerspink","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ekir.2024.09.014_bib36","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1475-2840-13-28","article-title":"The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus","volume":"13","author":"Cherney","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.ekir.2024.09.014_bib37","article-title":"Effect of sodium-glucose Cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: A systematic review and meta-analysis of 43 randomized control trials with 22 528 patients","volume":"6","author":"Mazidi","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.ekir.2024.09.014_bib38","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1681\/ASN.2008101086","article-title":"Cellular origins of Type IV collagen networks in developing glomeruli","volume":"20","author":"Abrahamson","year":"2009","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2024.09.014_bib39","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s00467-020-04819-6","article-title":"Clinical practice recommendations for the diagnosis and management of Alport syndrome in children, adolescents, and young adults-an update for 2020","volume":"36","author":"Kashtan","year":"2021","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2024.09.014_bib40","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJMra1808786","article-title":"Insights into glomerular filtration and albuminuria","volume":"384","author":"Benzing","year":"2021","journal-title":"N\u00a0Engl J Med Ingelfinger JR"},{"key":"10.1016\/j.ekir.2024.09.014_bib41","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.2215\/CJN.08900722","article-title":"Estimated lifetime benefit of combined RAAS and SGLT2 inhibitor therapy in patients with albuminuric CKD without diabetes","volume":"17","author":"Vart","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2024.09.014_bib42","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1053\/j.ajkd.2020.04.016","article-title":"Mechanisms leading to differential hypoxia-inducible factor signaling in the diabetic kidney: modulation by SGLT2 inhibitors and hypoxia mimetics","volume":"77","author":"Packer","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2024.09.014_bib43","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1159\/000499597","article-title":"Canagliflozin prevents intrarenal angiotensinogen augmentation and mitigates kidney injury and hypertension in mouse model of type 2 diabetes mellitus","volume":"49","author":"Woods","year":"2019","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.ekir.2024.09.014_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002983","article-title":"Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: a systematic review and meta-analysis","volume":"16","author":"Menne","year":"2019","journal-title":"PLOS Med"},{"key":"10.1016\/j.ekir.2024.09.014_bib45","unstructured":"Gross O, Boeckhaus J, Weber LT, et\u00a0al. Friede T for the study group of the German Society of Pediatric Nephrology (GPN). Protocol and rationale for a randomized controlled SGLT2 inhibitor trial in pediatric and young adult populations with chronic kidney disease: Double PRO-TECT Alport. Nephrol Dial Transplant."}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024924019429?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024924019429?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T04:08:55Z","timestamp":1733198935000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024924019429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":45,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S2468024924019429"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2024.09.014","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SGLT2-Inhibition in Patients With Alport Syndrome","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2024.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}